You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Recurrent or Metastatic Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cadonilimab in Recurrent or Metastatic Cervical Cancer

Not yet recruiting
  • Recurrent or Metastatic Cervical Cancer
  • (no location specified)
Nov 23, 2023

Cervical Cancer Trial (Nimotuzumab?Tislelizumab)

Not yet recruiting
  • Cervical Cancer
  • (no location specified)
Sep 9, 2023

Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer Trial (Pembrolizumab, Lenvatinib)

Not yet recruiting
  • Recurrent Vulvar Cancer
  • +3 more
  • (no location specified)
Jun 12, 2023

AK104 Combined With I-125 Brachytherapy for Recurrent or

Not yet recruiting
  • Cervical Cancer
  • Iodine-125 particle brachytherapy
  • AK104
  • (no location specified)
Sep 25, 2023

Pancreatic Cancer Metastatic Trial (C3 (Metformin, Simvastatin, and Digoxin))

Not yet recruiting
  • Pancreatic Cancer Metastatic
  • C3 (Metformin, Simvastatin, and Digoxin)
  • (no location specified)
Sep 1, 2023

Metastatic Breast Cancer Trial (SKB264, Eribulin, Capecitabine)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Oct 7, 2023

Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer Trial in Shanghai (BL-B01D1, SI-B003)

Not yet recruiting
  • Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 12, 2023

Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,

Terminated
  • Recurrent Gynecological Cancer
  • +10 more
  • Boston, Massachusetts
    Martin King
Oct 4, 2022

Breast Cancer Trial (SHR-A1811, Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Apr 3, 2023

HER2-PositiveRecurrent or Metastatic Breast Cancer Trial (SHR-A1811 Injection, SHR-A1811 Injection ; Pertuzumab Injection,

Not yet recruiting
  • HER2-PositiveRecurrent or Metastatic Breast Cancer
  • SHR-A1811 Injection
  • +2 more
  • (no location specified)
Sep 21, 2023

Persistent, Recurrent, or Metastatic Cervical Cancer Trial in Shanghai (GLS-010, Placebo, paclitaxel)

Not yet recruiting
  • Persistent, Recurrent, or Metastatic Cervical Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Hospital
Apr 4, 2023

Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy Trial run by the Precigen, Inc (PRGN-2009 plus Pembrolizumab,

Not yet recruiting
  • Cervical Cancer
  • +2 more
  • PRGN-2009 plus Pembrolizumab
  • Pembrolizumab alone
  • Bethesda, Maryland
    National Institute of Health
Nov 27, 2023

Recurrent or Metastatic Colorectal Cancer Trial (Nelmastobart and Capecitabine)

Not yet recruiting
  • Recurrent or Metastatic Colorectal Cancer
  • Nelmastobart and Capecitabine
  • (no location specified)
Aug 6, 2023

Bladder Cancer Trial in Tianjin (Cadonilimab)

Recruiting
  • Bladder Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 23, 2023

Metastatic Cervical Cancer Trial (Tislelizumab, Sitravatinib)

Not yet recruiting
  • Metastatic Cervical Cancer
  • (no location specified)
Jan 31, 2023

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Trial in Pittsburgh (Pembrolizumab, Carboplatin,

Not yet recruiting
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 18, 2023

GENE EXPRESSION PROFILING IN A VALIDATION COHORT OF LOCALLY

Not yet recruiting
  • Salivary Gland Cancer
  • Observation
  • (no location specified)
Oct 13, 2023

Lung Cancer Stage IV Trial in Maastricht (Radiation)

Not yet recruiting
  • Lung Cancer Stage IV
  • Radiation
  • Maastricht, Netherlands
    Maastricht Radiation Oncology (Maastro)
Aug 29, 2023

NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +32 more
  • (no location specified)
Mar 30, 2023

Uterine Cervical Tumors, Cancer of Cervix, Cervical Cancer Trial (Cadonilimab, Nab paclitaxel)

Not yet recruiting
  • Uterine Cervical Neoplasms
  • +5 more
  • (no location specified)
Apr 9, 2023

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer Trial (KN026, HB1801, Pertuzumab)

Not yet recruiting
  • First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
  • (no location specified)
Apr 20, 2023

Vulvar Cancer Trial in China (AK104)

Not yet recruiting
  • Vulvar Cancer
  • Fuzhou, Fujian, China
  • +5 more
Jun 27, 2023

Breast Tumors Trial in Hangzhou (Sindilimab, Nab-paclitaxel, Lenvatinib)

Not yet recruiting
  • Breast Neoplasms
  • Hangzhou, Zhejiang, China
    ZhejiangCH
Nov 17, 2023

Endometrioid Endometrial Cancer Trial (Narazaciclib, Letrozole 2.5mg)

Not yet recruiting
  • Endometrioid Endometrial Cancer
  • (no location specified)
Feb 1, 2023

Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma Trial in United States

Not yet recruiting
  • Adenoid Cystic Carcinoma
  • +2 more
  • San Francisco, California
  • +5 more
Nov 1, 2023